» Articles » PMID: 33707593

Atrial High‑rate Episodes and Risk of Major Adverse Cardiovascular Events in Patients with Dual Chamber Permanent Pacemakers: a Retrospective Study

Overview
Journal Sci Rep
Specialty Science
Date 2021 Mar 12
PMID 33707593
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Patients with atrial high-rate episodes (AHRE) are at higher risk of major adverse cardiovascular events (MACE). The cutoff threshold for AHRE duration for MACE, with/without history of atrial fibrillation (AF) or myocardial infarction (MI), is unknown. A total of 481 consecutive patients with/without history of AF or MI receiving dual-chamber pacemaker implantation were included. The primary outcome was a composite endpoint of MACE after AHRE ≥ 5 min, ≥ 6 h, and ≥ 24 h. AHRE was defined as > 175 bpm (MEDTRONIC) or > 200 bpm (BIOTRONIK) lasting ≥ 5 min. Cox regression analysis with time-dependent covariates was conducted. Patients' mean age was 75.3 ± 10.7 years and 188 (39.1%) developed AHRE ≥ 5 min, 115 (23.9%) ≥ 6 h, and 83 (17.3%) ≥ 24 h. During follow-up (median 39.9 ± 29.8 months), 92 MACE occurred (IR 5.749%/year, 95% CI 3.88-5.85). AHRE ≥ 5 min (HR 5.252, 95% CI 2.575-10.715, P < 0.001) and ≥ 6 h (HR 2.548, 95% CI 1.284-5.058, P = 0.007) was independently associated with MACE, but not AHRE ≥ 24 h. Patients with history of MI (IR 17.80%/year) had higher MACE incidence than those without (IR 3.77%/year, p = 0.001). Significant differences were found between MACE patients with/without history of AF in AHRE ≥ 5 min but not AHRE ≥ 6 h or ≥ 24 h. Patients with dual-chamber pacemakers who develop AHRE have increased risk of MACE, particularly after history of AF or MI.

Citing Articles

Mid-term comparison of new-onset AHRE between His bundle and left bundle branch area pacing in patients with AV block.

Pestrea C, Cicala E, Enache R, Rusu M, Gavrilescu R, Vaduva A J Arrhythm. 2025; 41(1):e70009.

PMID: 39906094 PMC: 11792577. DOI: 10.1002/joa3.70009.


CaMKIIδ-dependent dysregulation of atrial Na homeostasis promotes pro-arrhythmic activity in an obstructive sleep apnea mouse model.

Hegner P, Ofner F, Schaner B, Gugg M, Trum M, Lauerer A Front Pharmacol. 2024; 15:1411822.

PMID: 38966545 PMC: 11222670. DOI: 10.3389/fphar.2024.1411822.


Oral Anticoagulation in Patients With Atrial High-Rate Episodes: Focus on Clinical Implications.

Dimou S, Mystakidi V, Chiotis S, Daios S, Kalantzis C, Milaras N Cureus. 2023; 15(10):e46686.

PMID: 37942367 PMC: 10629590. DOI: 10.7759/cureus.46686.


The Differential Prognostic Impact of Long-Duration Atrial High-Rate Episodes Detected by Cardiac Implantable Electronic Devices between Patients with and without a History of Atrial Fibrillation.

Ishiguchi H, Yoshiga Y, Shimizu A, Ueyama T, Ono M, Fukuda M J Clin Med. 2022; 11(6).

PMID: 35330056 PMC: 8954400. DOI: 10.3390/jcm11061732.


How should I treat patients with subclinical atrial fibrillation and atrial high-rate episodes? Current evidence and clinical importance.

Kreimer F, Mugge A, Gotzmann M Clin Res Cardiol. 2022; 111(9):994-1009.

PMID: 35292844 PMC: 9424173. DOI: 10.1007/s00392-022-02000-7.


References
1.
Kamel H, Okin P, Elkind M, Iadecola C . Atrial Fibrillation and Mechanisms of Stroke: Time for a New Model. Stroke. 2016; 47(3):895-900. PMC: 4766055. DOI: 10.1161/STROKEAHA.115.012004. View

2.
Tseng C, Chung W, Li C, Tsai T, Lee C, Hsueh S . Statins reduce new-onset atrial fibrillation after acute myocardial infarction: A nationwide study. Medicine (Baltimore). 2020; 99(2):e18517. PMC: 6959943. DOI: 10.1097/MD.0000000000018517. View

3.
Bayturan O, Puri R, Tuzcu E, Shao M, Wolski K, Schoenhagen P . Atrial fibrillation, progression of coronary atherosclerosis and myocardial infarction. Eur J Prev Cardiol. 2016; 24(4):373-381. DOI: 10.1177/2047487316679265. View

4.
Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B . 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur J Cardiothorac Surg. 2016; 50(5):e1-e88. DOI: 10.1093/ejcts/ezw313. View

5.
Gelbenegger G, Postula M, Pecen L, Halvorsen S, Lesiak M, Schoergenhofer C . Aspirin for primary prevention of cardiovascular disease: a meta-analysis with a particular focus on subgroups. BMC Med. 2019; 17(1):198. PMC: 6827248. DOI: 10.1186/s12916-019-1428-0. View